Schering AG/Berlex Leukine To Enter Phase III For Crohn's In Early 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Berlex’ Leukine is expected to enter Phase III development for moderately to severely active Crohn’s disease in early 2004, but the primary endpoint to be used is still being negotiated with FDA, the Schering AG subsidiary said Oct. 14.